Fine-needle Diathermy Combined With Subconjunctival Bevacizumab for Corneal Neovascularization

The goal of this clinical trial is to evaluate the efficacy and safety of combined fine-needle diathermy and subconjunctival Bevacizumab injection in patients with corneal neovascularization. The main questions it aims to answer are: Does combined fine-needle diathermy and subconjunctival Bevacizumab injection promote regression of corneal neovascularization? Is the treatment safe and well tolerated by patients? Participants will: Undergo a baseline evaluation, including assessment of disease duration, ocular history, systemic medical history, and presenting symptoms. Undergo a detailed ophthalmic evaluation, including best-corrected visual acuity, intraocular pressure measurement, slit-lamp examination, corneal photography, and anterior segment optical coherence tomography (AS-OCT). Provide informed consent after explanation of potential risks and benefits of the procedure.

Inclusion Criteria: * Age over 18 years. * Diagnosis of corneal neovascularization involving at least one quadrant of the cornea, confirmed by slit-lamp examination. * Corneal neovascularization is stable with no evidence of progression for at least 4 weeks. * Agreement to participate in the study and ability to comply with outpatient follow-up requirements Exclusion Criteria: * Pregnant or breastfeeding women. * History of hypersensitivity or allergy to bevacizumab or any component of the study medication. * Presence of severe systemic disease that would preclude study participation or surgical intervention, including coagulation disorders or uncontrolled cardiovascular disease. * Active ocular infection or acute conjunctivitis at the time of enrollment. * Persistent corneal epithelial defect or delayed corneal epithelial healing. * History of ocular surgery within 3 months before study enrollment. * Corneal neovascularization associated with uncontrolled secondary glaucoma. * Inability or unwillingness to comply with study treatment or follow-up visits.